Drug Trial Radar · NCT07465653
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Dec 8, 2026
Study completion Dec 8, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
HJB647 low doseDrug
Study drug low dose in capsule form
HJB647 high doseDrug
Study drug high dose in capsule form
PlaceboOther
Placebo control in capsule form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Up to 33 days
- Number of participants with clinically significant changes in vital signsTime frame: Up to 33 days
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Synergy Healthcare
Bradenton, Florida · Recruiting
Nature Coast Clinical Research LLC
Inverness, Florida · Recruiting
Jacksonville Center for Clinical
Jacksonville, Florida · Recruiting
Inpatient Research Clinical LLC
Miami Lakes, Florida · Recruiting
Flourish Research
Winter Park, Florida · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Sherbrooke, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.